Experimental Monthly Semaglutide Hydrogel Shows Promise for Improved Diabetes and Obesity Treatment
A novel injectable semaglutide-loaded hydrogel formulation demonstrates extended drug release over one month and good tolerability in preclinical studies, potentially improving patient adherence and treatment outcomes for type 2 diabetes and obesity.